vs
Celldex Therapeutics, Inc.（CLDX）与QuidelOrtho Corp（QDEL）财务数据对比。点击上方公司名可切换其他公司
QuidelOrtho Corp的季度营收约是Celldex Therapeutics, Inc.的5832.5倍（$699.9M vs $120.0K）。QuidelOrtho Corp净利率更高（-104.7% vs -67764.2%，领先67659.4%）。QuidelOrtho Corp同比增速更快（-3.7% vs -89.8%）。Celldex Therapeutics, Inc.自由现金流更多（$-65.2M vs $-94.7M）。过去两年QuidelOrtho Corp的营收复合增速更高（-2.9% vs -12.3%）
Celldex Therapeutics是一家临床阶段生物制药企业，专注于开发针对难治性癌症和罕见免疫疾病的靶向免疫疗法，管线涵盖抗体药物偶联物、单克隆抗体等创新疗法，致力于满足大量未被满足的临床医疗需求。
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
CLDX vs QDEL — 直观对比
营收规模更大
QDEL
是对方的5832.5倍
$120.0K
营收增速更快
QDEL
高出86.0%
-89.8%
净利率更高
QDEL
高出67659.4%
-67764.2%
自由现金流更多
CLDX
多$29.5M
$-94.7M
两年增速更快
QDEL
近两年复合增速
-12.3%
损益表 — Q4 2025 vs Q3 2026
| 指标 | | |
|---|---|---|
| 营收 | $120.0K | $699.9M |
| 净利润 | $-81.3M | $-733.0M |
| 毛利率 | — | — |
| 营业利润率 | -72628.3% | -100.7% |
| 净利率 | -67764.2% | -104.7% |
| 营收同比 | -89.8% | -3.7% |
| 净利润同比 | -72.7% | -3583.4% |
| 每股收益（稀释后） | $-1.23 | $-10.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLDXQDEL
| Q4 25 | $120.0K | — | ||
| Q3 25 | $0 | $699.9M | ||
| Q2 25 | $730.0K | $613.9M | ||
| Q1 25 | $695.0K | $692.8M | ||
| Q4 24 | $1.2M | $707.8M | ||
| Q3 24 | $3.2M | $727.1M | ||
| Q2 24 | $2.5M | $637.0M | ||
| Q1 24 | $156.0K | $711.0M |
净利润CLDXQDEL
| Q4 25 | $-81.3M | — | ||
| Q3 25 | $-67.0M | $-733.0M | ||
| Q2 25 | $-56.6M | $-255.4M | ||
| Q1 25 | $-53.8M | $-12.7M | ||
| Q4 24 | $-47.1M | $-178.4M | ||
| Q3 24 | $-42.1M | $-19.9M | ||
| Q2 24 | $-35.8M | $-147.7M | ||
| Q1 24 | $-32.8M | $-1.7B |
营业利润率CLDXQDEL
| Q4 25 | -72628.3% | — | ||
| Q3 25 | — | -100.7% | ||
| Q2 25 | -8747.5% | -29.4% | ||
| Q1 25 | -9027.2% | 4.7% | ||
| Q4 24 | -4768.3% | -14.2% | ||
| Q3 24 | -1633.5% | 2.1% | ||
| Q2 24 | -1854.2% | -18.4% | ||
| Q1 24 | -26030.8% | -247.3% |
净利率CLDXQDEL
| Q4 25 | -67764.2% | — | ||
| Q3 25 | — | -104.7% | ||
| Q2 25 | -7753.4% | -41.6% | ||
| Q1 25 | -7740.4% | -1.8% | ||
| Q4 24 | -4007.8% | -25.2% | ||
| Q3 24 | -1320.0% | -2.7% | ||
| Q2 24 | -1434.8% | -23.2% | ||
| Q1 24 | -21030.8% | -239.9% |
每股收益（稀释后）CLDXQDEL
| Q4 25 | $-1.23 | — | ||
| Q3 25 | $-1.01 | $-10.78 | ||
| Q2 25 | $-0.85 | $-3.77 | ||
| Q1 25 | $-0.81 | $-0.19 | ||
| Q4 24 | $-0.71 | $-2.54 | ||
| Q3 24 | $-0.64 | $-0.30 | ||
| Q2 24 | $-0.54 | $-2.20 | ||
| Q1 24 | $-0.56 | $-25.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $518.6M | $98.1M |
| 总债务越低越好 | — | $2.5B |
| 股东权益账面价值 | $527.2M | $2.0B |
| 总资产 | $583.0M | $5.7B |
| 负债/权益比越低杠杆越低 | — | 1.23× |
8季度趋势，按日历期对齐
现金及短期投资CLDXQDEL
| Q4 25 | $518.6M | — | ||
| Q3 25 | $583.2M | $98.1M | ||
| Q2 25 | $630.3M | $151.7M | ||
| Q1 25 | $673.3M | $127.1M | ||
| Q4 24 | $725.3M | $98.3M | ||
| Q3 24 | $756.0M | $143.7M | ||
| Q2 24 | $802.3M | $107.0M | ||
| Q1 24 | $823.8M | $78.5M |
总债务CLDXQDEL
| Q4 25 | — | — | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B |
股东权益CLDXQDEL
| Q4 25 | $527.2M | — | ||
| Q3 25 | $598.4M | $2.0B | ||
| Q2 25 | $655.4M | $2.8B | ||
| Q1 25 | $703.0M | $3.0B | ||
| Q4 24 | $747.0M | $3.0B | ||
| Q3 24 | $785.9M | $3.2B | ||
| Q2 24 | $813.7M | $3.2B | ||
| Q1 24 | $838.6M | $3.3B |
总资产CLDXQDEL
| Q4 25 | $583.0M | — | ||
| Q3 25 | $648.4M | $5.7B | ||
| Q2 25 | $692.4M | $6.4B | ||
| Q1 25 | $739.5M | $6.5B | ||
| Q4 24 | $792.3M | $6.4B | ||
| Q3 24 | $823.2M | $6.8B | ||
| Q2 24 | $845.6M | $6.7B | ||
| Q1 24 | $868.8M | $6.7B |
负债/权益比CLDXQDEL
| Q4 25 | — | — | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | — | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-63.9M | $-45.5M |
| 自由现金流经营现金流 - 资本支出 | $-65.2M | $-94.7M |
| 自由现金流率自由现金流/营收 | -54350.8% | -13.5% |
| 资本支出强度资本支出/营收 | 1067.5% | 7.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-213.7M | $-153.1M |
8季度趋势，按日历期对齐
经营现金流CLDXQDEL
| Q4 25 | $-63.9M | — | ||
| Q3 25 | $-48.6M | $-45.5M | ||
| Q2 25 | $-44.0M | $-46.8M | ||
| Q1 25 | $-54.4M | $65.6M | ||
| Q4 24 | $-32.5M | $63.7M | ||
| Q3 24 | $-55.3M | $117.9M | ||
| Q2 24 | $-29.3M | $-97.9M | ||
| Q1 24 | $-40.6M | $-700.0K |
自由现金流CLDXQDEL
| Q4 25 | $-65.2M | — | ||
| Q3 25 | $-49.1M | $-94.7M | ||
| Q2 25 | $-44.7M | $-84.3M | ||
| Q1 25 | $-54.6M | $9.4M | ||
| Q4 24 | $-33.2M | $16.5M | ||
| Q3 24 | $-55.9M | $71.4M | ||
| Q2 24 | $-29.6M | $-133.2M | ||
| Q1 24 | $-41.0M | $-66.8M |
自由现金流率CLDXQDEL
| Q4 25 | -54350.8% | — | ||
| Q3 25 | — | -13.5% | ||
| Q2 25 | -6127.8% | -13.7% | ||
| Q1 25 | -7861.4% | 1.4% | ||
| Q4 24 | -2828.3% | 2.3% | ||
| Q3 24 | -1751.2% | 9.8% | ||
| Q2 24 | -1185.0% | -20.9% | ||
| Q1 24 | -26270.5% | -9.4% |
资本支出强度CLDXQDEL
| Q4 25 | 1067.5% | — | ||
| Q3 25 | — | 7.0% | ||
| Q2 25 | 99.7% | 6.1% | ||
| Q1 25 | 38.1% | 8.1% | ||
| Q4 24 | 64.3% | 6.7% | ||
| Q3 24 | 17.1% | 6.4% | ||
| Q2 24 | 11.0% | 5.5% | ||
| Q1 24 | 220.5% | 9.3% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLDX
暂无分部数据
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
